AU2019216305B2 - Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a G-CSF agent - Google Patents

Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a G-CSF agent Download PDF

Info

Publication number
AU2019216305B2
AU2019216305B2 AU2019216305A AU2019216305A AU2019216305B2 AU 2019216305 B2 AU2019216305 B2 AU 2019216305B2 AU 2019216305 A AU2019216305 A AU 2019216305A AU 2019216305 A AU2019216305 A AU 2019216305A AU 2019216305 B2 AU2019216305 B2 AU 2019216305B2
Authority
AU
Australia
Prior art keywords
plinabulin
csf
chemotherapy
administration
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019216305A
Other languages
English (en)
Other versions
AU2019216305A1 (en
Inventor
Lan Huang
George Kenneth Lloyd
Ramon Mohanlal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeyondSpring Pharmaceuticals Inc
Original Assignee
BeyondSpring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BeyondSpring Pharmaceuticals Inc filed Critical BeyondSpring Pharmaceuticals Inc
Publication of AU2019216305A1 publication Critical patent/AU2019216305A1/en
Application granted granted Critical
Publication of AU2019216305B2 publication Critical patent/AU2019216305B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
AU2019216305A 2018-02-01 2019-01-30 Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a G-CSF agent Active AU2019216305B2 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862625290P 2018-02-01 2018-02-01
US62/625,290 2018-02-01
US201862713486P 2018-08-01 2018-08-01
US62/713,486 2018-08-01
US201862749060P 2018-10-22 2018-10-22
US62/749,060 2018-10-22
US201862757648P 2018-11-08 2018-11-08
US62/757,648 2018-11-08
PCT/US2019/015867 WO2019152530A1 (en) 2018-02-01 2019-01-30 Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a g-csf agent

Publications (2)

Publication Number Publication Date
AU2019216305A1 AU2019216305A1 (en) 2020-08-27
AU2019216305B2 true AU2019216305B2 (en) 2024-11-21

Family

ID=67479904

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019216305A Active AU2019216305B2 (en) 2018-02-01 2019-01-30 Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a G-CSF agent

Country Status (11)

Country Link
US (1) US20210030843A1 (https=)
EP (1) EP3746076A4 (https=)
JP (3) JP2021512121A (https=)
KR (2) KR20200116477A (https=)
CN (1) CN112105363A (https=)
AU (1) AU2019216305B2 (https=)
BR (1) BR112020015758A2 (https=)
CA (1) CA3089391A1 (https=)
IL (1) IL276197A (https=)
SG (1) SG11202006990TA (https=)
WO (1) WO2019152530A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383691B (es) 2015-03-06 2025-03-14 Beyondspring Pharmaceuticals Inc Método de tratamiento de cáncer asociado con una mutación de ras.
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
WO2017139231A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
RU2760348C2 (ru) 2016-06-06 2021-11-24 Бейондспринг Фармасьютикалс, Инк. Способ уменьшения нейтропении
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
US11267858B2 (en) 2019-05-31 2022-03-08 Spectrum Pharmaceuticals, Inc. Methods of treatment using G-CSF protein complex
US11684655B2 (en) 2019-05-31 2023-06-27 Spectrum Pharmaceuticals, Inc. Methods of treating neutorpenia using G-CSF protein complex
EP4045046A4 (en) * 2019-10-15 2024-01-10 Beyondspring Pharmaceuticals Inc. Methods and compositions for treating iron disorders
JP2023505506A (ja) * 2019-12-05 2023-02-09 ハンミ ファーマシューティカルズ カンパニー リミテッド 化学療法または放射線療法で誘導された好中球減少症を治療する方法
CA3186416A1 (en) * 2020-07-17 2022-01-20 John A. Barrett Methods of treating chemotherapy induced neutropenia using fixed doses of g-csf protein complex
WO2022133492A1 (en) * 2020-12-18 2022-06-23 Beyondspring Pharmaceuticals, Inc. Compositions and methods for generating anti-tumor immune response
KR102375269B1 (ko) * 2021-01-27 2022-03-17 한미약품 주식회사 단백질 액상 제제 및 이의 제조방법
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
FI131561B1 (en) * 2023-12-28 2025-06-30 Faron Pharmaceuticals Oy CLEVER-1 INHIBITOR TO PROMOTE HEMATOLOGICAL RECOVERY WHEN USING CHEMOTHERAPY
CN120682197A (zh) * 2024-03-19 2025-09-23 大连万春布林医药有限公司 普那布林的盐晶型
CN119371407A (zh) * 2024-06-27 2025-01-28 青岛海合生物科技有限公司 一种具有抗肿瘤功效的2,5-二酮哌嗪类化合物及其在制备治疗和/或预防中性粒细胞减少症的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214052A1 (en) * 2016-06-06 2017-12-14 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
WO2018144764A1 (en) * 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Method of reducing neutropenia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110132327A (ko) * 2009-01-16 2011-12-07 테바 파마슈티컬 인더스트리즈 리미티드 재조합 인간 알부민-인간 과립구 콜로니 자극 인자 융합 단백질의 신규 안정한 제형
JP6411523B2 (ja) * 2013-10-11 2018-10-24 ビヨンドスプリング インコーポレイテッド プリナブリン及びタキサンの組合せがん治療

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214052A1 (en) * 2016-06-06 2017-12-14 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
WO2018144764A1 (en) * 2017-02-01 2018-08-09 Beyondspring Pharmaceuticals, Inc. Method of reducing neutropenia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BLAYNEY DOUGLAS W ET AL, BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 128, no. 22, 2 December 2016 (2016-12-02), pages 2508, XP009505981, ISSN: 0006-4971 *

Also Published As

Publication number Publication date
US20210030843A1 (en) 2021-02-04
IL276197A (en) 2020-09-30
CA3089391A1 (en) 2019-08-08
SG11202006990TA (en) 2020-08-28
KR20260023097A (ko) 2026-02-20
JP2021512121A (ja) 2021-05-13
EP3746076A1 (en) 2020-12-09
WO2019152530A1 (en) 2019-08-08
JP2026026377A (ja) 2026-02-16
JP2024015120A (ja) 2024-02-01
RU2020126600A (ru) 2022-03-01
KR20200116477A (ko) 2020-10-12
EP3746076A4 (en) 2021-12-22
NZ766454A (en) 2024-02-23
BR112020015758A2 (pt) 2020-12-08
AU2019216305A1 (en) 2020-08-27
CN112105363A (zh) 2020-12-18

Similar Documents

Publication Publication Date Title
AU2019216305B2 (en) Composition and method for reducing chemotherapy-induced neutropenia via the administration of plinabulin and a G-CSF agent
US12458638B2 (en) Method of stimulating neutrophil survival and reducing neutropenia
JP7405881B2 (ja) 好中球減少症を低減させるための組成物および方法
CA3089226A1 (en) Composition and method for reducing thrombocytopenia via the administration of plinabulin
RU2798103C2 (ru) Композиция и способ уменьшения вызванной химиотерапией нейтропении с помощью введения плинабулина и агента г-ксф
NZ755858B2 (en) Method of reducing neutropenia
RU2790989C2 (ru) Способ уменьшения нейтропении
RU2790989C9 (ru) Способ уменьшения нейтропении
CA3026455C (en) Use of plinabulin for reducing neutropenia induced by chemotherapeutic agents
NZ748877B2 (en) Composition and method for reducing neutropenia

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)